| Title | A pilot study of irinotecan combined with 5-fluorouracil and leucovorin for the treatment of Chinese patients with locally advanced and metastatic gastric cancer. | | Author(s) | Li Q, Chen J, Zhao X, Yin X, Mei K, Zhou C, Cai X | | Institution | Department of Abdominal Cancer, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Sichuan, The People's Republic of China. qiuli108@yahoo.com.cn | | Source | Tumori 2009 Jul-Aug; 95(4):432-7. | | Abstract | AIMS AND BACKGROUND: The FOLFIRI regimen was evaluated for its anti-tumor activity and toxicity in Chinese patients with locally advanced and metastatic gastric cancer.
METHODS AND
STUDY DESIGN: Treatment consisted ofirinotecan, 180 mg/m2 (90-min infusion), leucovorin, 200 mg/m2 (2-h infusion), followed by 5-fluorouracil, 400 mg/m2 (bolus), and then 5-fluorouracil, 600 mg/m2 (22-h continuous infusion) on days 1 and 2, every 14 days.
RESULTS: Twenty-six patients, of whom 17 were pretreated, were included in the study. Partial response was observed in 9 patients (37.5%). The overall disease control rate was 83.3%. Median progression-free and overall survival was 6.8 and 11.2 months, respectively. Grade 3-4 neutropenia was observed in 6 patients (23.1%) and grade 2-3 diarrhea in 5 (19.2%). No treatment-related deaths occurred.
CONCLUSIONS: The results demonstrate that the FOLFIRI regimen is an active regimen with acceptable toxicity for Chinese patients with advanced and metastatic gastric cancer that merits further investigation in comparative trials. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
| | PubMed ID | 19856652 |
|
